XML 50 R10.htm IDEA: XBRL DOCUMENT
v3.23.2

Investments | 9 Months Ended
--- | ---
May 31, 2023
Investments [Abstract] |
Investments | Investments
| May 31, 2023 |  | August 31, 2022
| (Dollars in thousands)
Equity method investments: |  |  |
CF Industries Nitrogen, LLC | $ | 2,717,704 |  |  | $ | 2,641,604 |
Ventura Foods, LLC | 459,906 |  |  | 410,093 |
Ardent Mills, LLC | 258,539 |  |  | 250,857 |
TEMCO, LLC | 47,377 |  |  | 32,809 |
Other equity method investments | 286,810 |  |  | 265,913 |
Other investments | 135,398 |  |  | 126,730 |
Total investments | $ | 3,905,734 |  |  | $ | 3,728,006 |
Joint ventures and other investments in which we have significant ownership and influence, but not control, are accounted for in our condensed consolidated financial statements using the equity method of accounting. Our only significant equity method investment during the nine months ended May 31, 2023 and 2022, was CF Industries Nitrogen, LLC ("CF Nitrogen"), which is summarized below. In addition to recognition of our share of income from equity method investments, our equity method investments are evaluated for indicators of other-than-temporary impairment on an ongoing basis in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). Other investments consist primarily of investments in cooperatives without readily determinable fair values and are generally recorded at cost, unless an impairment or other observable market price change occurs requiring an adjustment. We have approximately $756.7 million in cumulative undistributed earnings from our equity method investees included in the investments balance as of May 31, 2023. CF Nitrogen We have a $2.7 billion investment in CF Nitrogen, a strategic venture with CF Industries Holdings, Inc. ("CF Industries"). The investment consists of an approximate 8% membership interest (based on product tons) in CF Nitrogen. We account for this investment using the hypothetical liquidation at book value method, recognizing our share of the earnings and losses of CF Nitrogen as equity income from investments in our Nitrogen Production segment based on our contractual claims on the entity's net assets pursuant to the liquidation provisions of CF Nitrogen's Limited Liability Company Agreement, adjusted for semiannual cash distributions. The following table provides summarized unaudited financial information for our equity method investment in CF Nitrogen for the nine months ended May 31, 2023 and 2022:
| Nine Months Ended May 31,
| 2023 |  | 2022
| (Dollars in thousands)
Net sales | $ | 4,200,120 |  |  | $ | 4,972,383 |
Gross profit | 1,898,265 |  |  | 2,682,653 |
Net earnings | 1,884,666 |  |  | 2,641,425 |
Earnings attributable to CHS Inc. | 330,855 |  |  | 497,289 |
Our investments in other equity method investees are not significant in relation to our condensed consolidated financial statements, either individually or in aggregate.

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for investments and other noncurrent assets. + References No definition available. + Details
Name: | us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration